Cholesterol Efflux Capacity and Measurement Assays: A Novel Biomarker of High-Density Lipoprotein (HDL) Function

Biomarkers of high-density lipoprotein (HDL) function may provide better cardiovascular risk discrimination compared to HDL-cholesterol (HDL-C) mass measurements. Cholesterol efflux from macrophages to plasma reflects the first critical step of reverse cholesterol transport (RCT) and is considered o...

Full description

Saved in:
Bibliographic Details
Published in:The American heart journal 2021-12, Vol.242, p.158-158
Main Authors: Korjian, Serge, Kazmi, Syed Hassan Abbas, Chi, Gerald, Kalayci, Arzu, Lee, Jane J., Zheng, Bo, Shaunik, Alka, Diditchenko, Svetlana A., Kingwell, Bronwyn A., Gibson, C. Michael
Format: Article
Language:English
Subjects:
Arteriosclerosis
Atherosclerosis
Biomarkers
Blood plasma
Cardiovascular diseases
Cholesterol
Density
Efflux
Health risks
High density lipoprotein
Macrophages
Population studies
Population-based studies
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Biomarkers of high-density lipoprotein (HDL) function may provide better cardiovascular risk discrimination compared to HDL-cholesterol (HDL-C) mass measurements. Cholesterol efflux from macrophages to plasma reflects the first critical step of reverse cholesterol transport (RCT) and is considered one of the key anti-atherosclerotic functions of HDL. Population-based studies in low and high-risk atherosclerotic cardiovascular disease (ASCVD) cohorts have consistently demonstrated an inverse relationship between the cholesterol efflux capacity (CEC) of human plasma and death or major adverse cardiovascular events (MACE) independent of endogenous HDL-C concentration. Despite the importance of CEC as a biomarker of HDL function and a potential surrogate for clinical outcomes, its measurement has not been standardized to a single, reliable, and reproducible assay. The methodologies to measure CEC vary, often making comparisons between studies difficult. In this presentation, we review the pathways of cholesterol efflux, reverse cholesterol transport, and describe the methodology of measuring CEC ex vivo and the findings linking CEC to human disease.
ISSN:0002-8703
1097-6744
DOI:10.1016/j.ahj.2021.10.034